Connor, Clark & Lunn Investment Management (CC&L)
VIGL

Connor, Clark & Lunn Investment Management (CC&L)’s Vigil Neuroscience VIGL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,178
Closed -$65.4K – 1714
2024
Q1 		$65.4K Buy
+19,178
New +$59.9K ﹤0.01% 1483

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s VIGL Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Vigil Neuroscience (VIGL) in Q2 2024, closing a stake of 19,178 shares — an estimated $65.4K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VIGL in Q1 2024 and held it in 1 quarter. The position peaked at $65.4K in Q1 2024. 58 funds tracked by Wall St. Rank hold VIGL as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Vigil Neuroscience position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 19,178 Vigil Neuroscience shares in Q2 2024, an estimated $65.4K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Vigil Neuroscience in Q1 2024 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Vigil Neuroscience position peaked at $65.4K in Q1 2024.
  • 58 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.